Avestar Capital LLC cut its holdings in Celgene Co. (NASDAQ:CELG) by 15.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,455 shares of the biopharmaceutical company’s stock after selling 448 shares during the period. Avestar Capital LLC’s holdings in Celgene were worth $136,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. HL Financial Services LLC grew its holdings in Celgene by 20.5% during the 3rd quarter. HL Financial Services LLC now owns 4,213 shares of the biopharmaceutical company’s stock valued at $377,000 after purchasing an additional 717 shares during the last quarter. FMR LLC grew its holdings in Celgene by 26.0% during the 3rd quarter. FMR LLC now owns 10,279,258 shares of the biopharmaceutical company’s stock valued at $919,890,000 after purchasing an additional 2,119,257 shares during the last quarter. ING Groep NV grew its holdings in Celgene by 116.3% during the 3rd quarter. ING Groep NV now owns 203,229 shares of the biopharmaceutical company’s stock valued at $18,187,000 after purchasing an additional 109,292 shares during the last quarter. Bangor Savings Bank grew its holdings in Celgene by 21.2% during the 3rd quarter. Bangor Savings Bank now owns 18,049 shares of the biopharmaceutical company’s stock valued at $1,615,000 after purchasing an additional 3,157 shares during the last quarter. Finally, IFM Investors Pty Ltd grew its holdings in Celgene by 12.3% during the 3rd quarter. IFM Investors Pty Ltd now owns 38,302 shares of the biopharmaceutical company’s stock valued at $3,428,000 after purchasing an additional 4,193 shares during the last quarter. Institutional investors own 72.70% of the company’s stock.

Several equities analysts recently commented on CELG shares. BidaskClub downgraded shares of Celgene from a “hold” rating to a “sell” rating in a report on Wednesday, October 24th. Mizuho set a $117.00 price target on shares of Celgene and gave the company a “buy” rating in a report on Tuesday, October 30th. Leerink Swann downgraded shares of Celgene from an “outperform” rating to a “market perform” rating in a report on Thursday, January 3rd. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Celgene in a report on Thursday, October 25th. Finally, Robert W. Baird upgraded shares of Celgene from a “neutral” rating to an “outperform” rating and set a $92.00 price target on the stock in a report on Friday, January 4th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $110.00.

Celgene stock opened at $87.26 on Tuesday. The stock has a market capitalization of $61.27 billion, a price-to-earnings ratio of 12.76, a P/E/G ratio of 0.46 and a beta of 1.44. The company has a debt-to-equity ratio of 4.06, a current ratio of 2.13 and a quick ratio of 1.99. Celgene Co. has a 1 year low of $58.59 and a 1 year high of $105.83.

ILLEGAL ACTIVITY WARNING: This report was published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.dailypolitical.com/2019/01/29/avestar-capital-llc-trims-stake-in-celgene-co-celg.html.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Read More: Bond

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.